CA2839608C - (7as,2's)-2-oxoclopidogrel as anti-thrombotic compounds - Google Patents

(7as,2's)-2-oxoclopidogrel as anti-thrombotic compounds Download PDF

Info

Publication number
CA2839608C
CA2839608C CA2839608A CA2839608A CA2839608C CA 2839608 C CA2839608 C CA 2839608C CA 2839608 A CA2839608 A CA 2839608A CA 2839608 A CA2839608 A CA 2839608A CA 2839608 C CA2839608 C CA 2839608C
Authority
CA
Canada
Prior art keywords
clopidogrel
formula
compound
isomers
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2839608A
Other languages
English (en)
French (fr)
Other versions
CA2839608A1 (en
Inventor
Ashok Kumar
Satish Rajanikant Soudagar
Thankachen Byju Nellithanath
Gaurav Sahal
Arpana Prashant Mathur
Sanjay Pandurang Gawade
Dinesh Kanji Bhadra
Devki Moje
Original Assignee
Ipca Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipca Laboratories Ltd filed Critical Ipca Laboratories Ltd
Publication of CA2839608A1 publication Critical patent/CA2839608A1/en
Application granted granted Critical
Publication of CA2839608C publication Critical patent/CA2839608C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2839608A 2011-06-27 2012-01-06 (7as,2's)-2-oxoclopidogrel as anti-thrombotic compounds Active CA2839608C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1848/MUM/2011 2011-06-27
IN1848MU2011 2011-06-27
PCT/IN2012/000021 WO2013001544A1 (en) 2011-06-27 2012-01-06 Anti-thrombotic compounds

Publications (2)

Publication Number Publication Date
CA2839608A1 CA2839608A1 (en) 2013-01-03
CA2839608C true CA2839608C (en) 2020-07-14

Family

ID=45495857

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2839608A Active CA2839608C (en) 2011-06-27 2012-01-06 (7as,2's)-2-oxoclopidogrel as anti-thrombotic compounds

Country Status (13)

Country Link
US (6) US20120329762A1 (de)
EP (2) EP2675813A4 (de)
JP (1) JP2014518260A (de)
KR (1) KR20140047082A (de)
CN (1) CN104245707A (de)
AU (1) AU2012277327B2 (de)
BR (1) BR112013033464A2 (de)
CA (1) CA2839608C (de)
MX (1) MX344435B (de)
RU (1) RU2604733C2 (de)
SG (1) SG195257A1 (de)
WO (1) WO2013001544A1 (de)
ZA (1) ZA201309411B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2668945A1 (de) * 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
CN107698620A (zh) 2015-06-23 2018-02-16 江苏天士力帝益药业有限公司 一种氘代噻吩并哌啶衍生物、制备方法及其应用
CN107304215A (zh) * 2016-04-20 2017-10-31 陕西合成药业股份有限公司 噻吩吡啶类衍生物及其制备方法和用途
US12188069B2 (en) 2018-01-31 2025-01-07 The Regents Of The University Of Michigan Biocatalyst and methods for synthesizing mixed disulfide conjugates of thienopyridine compounds
CN108685913B (zh) * 2018-07-31 2021-08-10 成都施贝康生物医药科技有限公司 含氧吡格雷光学异构体或其盐的组合物及制备方法和应用
CN109912595B (zh) * 2019-03-29 2020-08-25 成都施贝康生物医药科技有限公司 一种抗炎药物及其用途
CN111943958B (zh) 2019-05-17 2023-05-09 成都施贝康生物医药科技有限公司 四氢噻吩并吡啶化合物的b晶型及制法、组合物和应用
CN112076190B (zh) * 2019-06-14 2023-04-07 成都施贝康生物医药科技有限公司 一种含有难溶性噻吩并吡啶组合物的固体制剂及制备方法
WO2021070200A2 (en) * 2019-10-08 2021-04-15 Ipca Laboratories Limited Stable compositions of (7as,2's)-2-oxoclopidogrel and its pharmaceutical salts
CN111249241B (zh) * 2020-01-19 2023-06-27 成都施贝康生物医药科技有限公司 一种含有难溶性噻吩并吡啶组合物的固体制剂及制备方法
CN111138450B (zh) * 2020-01-19 2024-04-19 成都施贝康生物医药科技有限公司 一种抗炎化合物及其制法和用途
CN111150731A (zh) * 2020-01-19 2020-05-15 成都施贝康生物医药科技有限公司 含氧吡格雷光学异构体或其盐的组合物及应用
CN115518066A (zh) * 2022-06-17 2022-12-27 成都施贝康生物医药科技有限公司 一种用于治疗抗凝血的药物组合物及应用
CN115327003B (zh) * 2022-08-12 2024-03-12 成都施贝康生物医药科技有限公司 一种氧化氯吡格雷有关物质的检测方法
CN115656394A (zh) * 2022-08-12 2023-01-31 成都施贝康生物医药科技有限公司 一种氧化氯吡格雷有关物质的检测方法
CN115327004B (zh) * 2022-08-12 2024-01-26 成都施贝康生物医药科技有限公司 一种氧化氯吡格雷粗品的检测方法
CN115429797A (zh) * 2022-08-31 2022-12-06 成都施贝康生物医药科技有限公司 一种含氧氯吡格雷或其盐的组合物及其制备

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2530247B1 (fr) 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
FR2576901B1 (fr) * 1985-01-31 1987-03-20 Sanofi Sa Nouveaux derives de l'acide a-(oxo-2 hexahydro-2,4,5,6,7,7a thieno (3,2-c) pyridyl-5) phenyl acetique, leur procede de preparation et leur application therapeutique
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
FR2652579B1 (fr) * 1989-10-02 1992-01-24 Sanofi Sa Derives d'hydroxy-2 thiophene et furanne condenses avec un cycle azote, sur procede de preparation et leur application en therapeutique.
JPH10310586A (ja) * 1996-06-26 1998-11-24 Sankyo Co Ltd ヒドロピリジン類の新規医薬用途
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
TWI392681B (zh) * 2006-04-06 2013-04-11 Daiichi Sankyo Co Ltd 高純度普拉格雷及其酸加成鹽之製法
CN101885730B (zh) * 2009-05-13 2012-07-04 连云港恒邦医药科技有限公司 抗血栓的化合物
CN102863457B (zh) * 2010-02-02 2013-10-09 江苏威凯尔医药科技有限公司 光学活性2-羟基四氢噻吩并吡啶衍生物及其制备方法与在制药中的用途
CN102212069A (zh) * 2010-04-06 2011-10-12 刘桂坤 环烷衍生物及其制备方法和在心脑血管病药物上的应用
CN102212068A (zh) * 2010-04-06 2011-10-12 刘桂坤 噻吩衍生物及其制备方法和在药物上的应用
JP2013536220A (ja) * 2010-08-26 2013-09-19 アイピーシーエー ラボラトリーズ リミテッド 血栓症または塞栓を治療または予防するための方法

Also Published As

Publication number Publication date
AU2012277327B2 (en) 2017-04-27
US10105353B2 (en) 2018-10-23
RU2604733C2 (ru) 2016-12-10
CA2839608A1 (en) 2013-01-03
WO2013001544A1 (en) 2013-01-03
ZA201309411B (en) 2014-08-27
MX344435B (es) 2016-12-14
US8536337B2 (en) 2013-09-17
MX2013014946A (es) 2014-02-17
NZ618694A (en) 2016-03-31
US20130316987A1 (en) 2013-11-28
US20120329762A1 (en) 2012-12-27
EP2540729A1 (de) 2013-01-02
RU2014102362A (ru) 2015-08-10
US20120329763A1 (en) 2012-12-27
BR112013033464A2 (pt) 2017-01-24
WO2013001544A9 (en) 2014-09-12
CN104245707A (zh) 2014-12-24
KR20140047082A (ko) 2014-04-21
EP2675813A4 (de) 2014-04-30
US20140038924A1 (en) 2014-02-06
US20140031320A1 (en) 2014-01-30
SG195257A1 (en) 2013-12-30
US20130316986A1 (en) 2013-11-28
EP2675813A1 (de) 2013-12-25
JP2014518260A (ja) 2014-07-28
AU2012277327A1 (en) 2014-01-09

Similar Documents

Publication Publication Date Title
US10105353B2 (en) Anti-thrombotic compounds
US8541422B2 (en) Methods for the treatment or prophylaxis of thrombosis or embolism
KR20180016631A (ko) 광학활성 2-히드록시테트라히드로티에노피리딘 유도체 및 그 제조방법과 제약적 용도
JP2013526488A (ja) シアノ基を含有するチエノピリジンエステル誘導体、その調製方法、使用および組成物
HK1173148A (en) (7as, 2's)-2-oxoclopidogrel as anti-thrombotic compound
NZ618694B2 (en) Anti-thrombotic compounds
CN109912595B (zh) 一种抗炎药物及其用途
CN113227102B (zh) Par4抑制剂的结晶形式
CN103864816B (zh) 噻吩并四氢吡啶芳酸醚类化合物、制备方法及其应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170103